• Developing next-generation topical anti-fibrotic drug SNT-9465 for skin scarring
• Phase 1a/b trial to begin Q2 2025 targeting safety and scar improvement
• Builds on SOLARIA2 trial findings, solidifying position as leader in lysyl oxidase inhibitors

Syntara Limited is pleased to announce the development of a next-generation topical anti-fibrotic drug candidate, SNT-9465, as part of its expanded skin scarring program. This initiative builds on the success and findings of the SOLARIA2 trial with SNT-6302, which reinforced the potential of Syntara's pan-lysyl oxidase (pan-LOX) inhibitor programs for fibrotic conditions. Syntara's drug discovery team has developed SNT-9465 to achieve strong anti-scarring efficacy with an improved tolerability profile suitable for daily use. The company believes this next-generation compound offers a superior profile for clinical development and represents a potential breakthrough in treating hypertrophic and keloid scarring. The clinical development plan for SNT-9465, costing $2m which will be funded from existing cash reserves, is designed to initially demonstrate the drug's safety and tolerability and then gain insights into its ability to improve both the appearance and physical properties of hypertrophic scars. A Phase 1a dose escalation study in healthy volunteers to determine the optimal dose for complete lysyl oxidase inhibition will be followed by an open label Phase 1b extension, which will assess improvements in appearance and composition of hypertrophic scars less than 24 months old after three months daily treatment. Results are expected in the first half of 2026 and will support an FDA Investigational New Drug (IND) application, paving the way for a global development program targeting the first approved pharmacological treatment for skin scarring. In parallel, the University of Western Australia scarring program under the leadership of Professor Fiona Wood will focus on keloid scars, which differ biologically from hypertrophic scars and present unique challenges for patients. Syntara will support an exploratory clinical trial set to begin in the second quarter of 2025, with the company providing SNT-6302 along with financial and technical backing.

Syntara aims to deliver an IND ready program with evidence supporting the safety and efficacy of SNT-9465 in 2026. The additional clinical development program with the University of Western Australia and the Fiona Wood Foundation will allow Syntara to expand the label indications into other scar types, further de-risking the company as an investment.